Brian T Helfand1, Carly A Conran, Jianfeng Xu, William J Catalona. 1. aDepartment of Surgery, NorthShore University HealthSystem, Program for Personalized Cancer Care, Evanston bDepartment of Urology, Northwestern University, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: To provide an overview of how genetic, serum, and urine biomarkers can help identify men at high risk for prostate cancer (PCa) and aggressive disease and men who would benefit from prostate biopsy. RECENT FINDINGS: Screening for PCa is controversial because of concerns about overdiagnosis and overtreatment of nonlife-threatening tumors. Therefore, an approach to screening that includes a detailed family history with genetic testing of risk single nucleotide polymorphisms and high-penetrance genetic variants should be considered. After an elevated serum prostate-specific antigen (PSA) level has been confirmed, obtaining additional information (family history, biomarkers, and imaging) should be considered before recommending a prostate biopsy. SUMMARY: There are now genetic tests that can help identify men who would benefit from PSA testing. Additional biomarker and imaging tests should be offered to those men who are confirmed to have elevated PSA values. These new biomarkers and imaging tests can improve the specificity of PSA testing while missing a small percentage of high-grade tumors. The path forward involves a multiparametric risk assessment based on clinical data and these new tests.
PURPOSE OF REVIEW: To provide an overview of how genetic, serum, and urine biomarkers can help identify men at high risk for prostate cancer (PCa) and aggressive disease and men who would benefit from prostate biopsy. RECENT FINDINGS: Screening for PCa is controversial because of concerns about overdiagnosis and overtreatment of nonlife-threatening tumors. Therefore, an approach to screening that includes a detailed family history with genetic testing of risk single nucleotide polymorphisms and high-penetrance genetic variants should be considered. After an elevated serum prostate-specific antigen (PSA) level has been confirmed, obtaining additional information (family history, biomarkers, and imaging) should be considered before recommending a prostate biopsy. SUMMARY: There are now genetic tests that can help identify men who would benefit from PSA testing. Additional biomarker and imaging tests should be offered to those men who are confirmed to have elevated PSA values. These new biomarkers and imaging tests can improve the specificity of PSA testing while missing a small percentage of high-grade tumors. The path forward involves a multiparametric risk assessment based on clinical data and these new tests.
Authors: Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs Journal: Eur Urol Date: 2016-12-15 Impact factor: 20.096
Authors: Christophe Rosty; Michael D Walsh; Noralane M Lindor; Stephen N Thibodeau; Erin Mundt; Steven Gallinger; Melyssa Aronson; Aaron Pollett; John A Baron; Sally Pearson; Mark Clendenning; Rhiannon J Walters; Belinda N Nagler; William J Crawford; Joanne P Young; Ingrid Winship; Aung Ko Win; John L Hopper; Mark A Jenkins; Daniel D Buchanan Journal: Fam Cancer Date: 2014-12 Impact factor: 2.375
Authors: Rui Henrique; Carmen Jerónimo; Manuel R Teixeira; Mohammad O Hoque; André L Carvalho; Irene Pais; Franclim R Ribeiro; Jorge Oliveira; Carlos Lopes; David Sidransky Journal: Mol Cancer Res Date: 2006-01 Impact factor: 5.852
Authors: James A Eastham; Elyn Riedel; Peter T Scardino; Moshe Shike; Martin Fleisher; Arthur Schatzkin; Elaine Lanza; Lianne Latkany; Colin B Begg Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer Journal: Cancer Causes Control Date: 2007-11-20 Impact factor: 2.506
Authors: Ali Amin Al Olama; Zsofia Kote-Jarai; Fredrick R Schumacher; Fredrik Wiklund; Sonja I Berndt; Sara Benlloch; Graham G Giles; Gianluca Severi; David E Neal; Freddie C Hamdy; Jenny L Donovan; David J Hunter; Brian E Henderson; Michael J Thun; Michael Gaziano; Edward L Giovannucci; Afshan Siddiq; Ruth C Travis; David G Cox; Federico Canzian; Elio Riboli; Timothy J Key; Gerald Andriole; Demetrius Albanes; Richard B Hayes; Johanna Schleutker; Anssi Auvinen; Teuvo L J Tammela; Maren Weischer; Janet L Stanford; Elaine A Ostrander; Cezary Cybulski; Jan Lubinski; Stephen N Thibodeau; Daniel J Schaid; Karina D Sorensen; Jyotsna Batra; Judith A Clements; Suzanne Chambers; Joanne Aitken; Robert A Gardiner; Christiane Maier; Walther Vogel; Thilo Dörk; Hermann Brenner; Tomonori Habuchi; Sue Ingles; Esther M John; Joanne L Dickinson; Lisa Cannon-Albright; Manuel R Teixeira; Radka Kaneva; Hong-Wei Zhang; Yong-Jie Lu; Jong Y Park; Kathleen A Cooney; Kenneth R Muir; Daniel A Leongamornlert; Edward Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Dudderidge; Chris Ogden; Colin S Cooper; Artitaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas English; Jarmo Virtamo; Loic Le Marchand; Daniele Campa; Rudolf Kaaks; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Meredith Yeager; Angela Cox; Mariana C Stern; Roman Corral; Markus Aly; William Isaacs; Jan Adolfsson; Jianfeng Xu; S Lilly Zheng; Tiina Wahlfors; Kimmo Taari; Paula Kujala; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Ruth Frikke-Schmidt; Stig E Bojesen; Liesel M FitzGerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Antje Rinckleb; Manuel Luedeke; Kathleen Herkommer; Andreas Meyer; Jürgen Serth; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Amanda Spurdle; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Pedro Pinto; Joana Santos; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; Craig Teerlink; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Stephen Chanock; Henrik Gronberg; Christopher A Haiman; Peter Kraft; Douglas F Easton; Rosalind A Eeles Journal: Hum Mol Genet Date: 2012-10-12 Impact factor: 6.150
Authors: Carly A Conran; Rong Na; Haitao Chen; Deke Jiang; Xiaoling Lin; S Lilly Zheng; Charles B Brendler; Jianfeng Xu Journal: Asian J Androl Date: 2016 Jul-Aug Impact factor: 3.285
Authors: Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson Journal: N Engl J Med Date: 2016-07-06 Impact factor: 91.245